These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 21889343)
1. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Choi SE; Weerasinghe SV; Pflum MK Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343 [TBL] [Abstract][Full Text] [Related]
2. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity. Negmeldin AT; Pflum MKH Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461 [TBL] [Abstract][Full Text] [Related]
3. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position. Choi SE; Pflum MK Bioorg Med Chem Lett; 2012 Dec; 22(23):7084-6. PubMed ID: 23089527 [TBL] [Abstract][Full Text] [Related]
5. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid. Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198 [TBL] [Abstract][Full Text] [Related]
6. Phosphorus containing analogues of SAHA as inhibitors of HDACs. Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164 [TBL] [Abstract][Full Text] [Related]
7. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells. Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592 [TBL] [Abstract][Full Text] [Related]
8. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817 [TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells. You BR; Han BR; Park WH Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148 [TBL] [Abstract][Full Text] [Related]
10. Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity. Negmeldin AT; Padige G; Bieliauskas AV; Pflum MK ACS Med Chem Lett; 2017 Mar; 8(3):281-286. PubMed ID: 28337317 [TBL] [Abstract][Full Text] [Related]
11. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC). Tambunan US; Bramantya N; Parikesit AA BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132 [TBL] [Abstract][Full Text] [Related]
12. Discovery of the first histone deacetylase 6/8 dual inhibitors. Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185 [TBL] [Abstract][Full Text] [Related]
13. (7-Diethylaminocoumarin-4-yl)methyl ester of suberoylanilide hydroxamic acid as a caged inhibitor for photocontrol of histone deacetylase activity. Ieda N; Yamada S; Kawaguchi M; Miyata N; Nakagawa H Bioorg Med Chem; 2016 Jun; 24(12):2789-93. PubMed ID: 27143132 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors. Liu R; Wang J; Tang W; Fang H Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204 [TBL] [Abstract][Full Text] [Related]
15. Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition. King K; Hauser AT; Melesina J; Sippl W; Jung M Molecules; 2018 Feb; 23(2):. PubMed ID: 29393896 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors. Zhang S; Huang W; Li X; Yang Z; Feng B Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653 [TBL] [Abstract][Full Text] [Related]
17. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. Zhang Y; Feng J; Liu C; Fang H; Xu W Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698 [TBL] [Abstract][Full Text] [Related]
19. Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors. Singh RK; Mandal T; Balasubramanian N; Cook G; Srivastava DK Anal Biochem; 2011 Jan; 408(2):309-15. PubMed ID: 20816742 [TBL] [Abstract][Full Text] [Related]
20. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Li D; Marchenko ND; Moll UM Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]